Safety and Effectiveness of an Investigational Agent (GM-611) in Patients With Diabetic Gastroparesis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This study is intended to evaluate the potential to relieve the symptoms associated with
gastroparesis during 12 weeks of treatment with oral tablets given twice a day of GM-611 5mg,
10mg or placebo to type I or II diabetics who require insulin.
Additionally the study will evaluate the safety and tolerability of GM-611 compared to
placebo, the levels of GM-611 in the blood, and the possible effect of GM-611 on diabetic
control.